Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation
- 20 August 2019
- journal article
- research article
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 24 (10) , 1229-1235
Abstract
Exenatide (EX), a glucagon-like peptide-1 receptor agonist, is used to treat diabetes mellitus. However, its short half-life necessitates frequent administration and fluctuations in its plasma concentration may cause adverse effects. Previously, we developed glycolic acid acylated EX, which showed a good glucose-lowering effect. However, the release of lactic acid (LA) acylated exenatide (LA-EX) as an acylated adduct in EX microspheres has not been studied. Here, we investigated the biological properties of LA-EX. Additionally, LA-EX-loaded microspheres were formulated by an emulsion–solvent evaporation method and their in vitro characteristics, in vivo pharmacokinetic properties, and antidiabetic activities were evaluated. Pharmacokinetic studies revealed that the t1/2 of LA-EX (5.95 h) was 2.3-fold longer than that of EX. The antidiabetic activities of LA-EX in db/db mice were similar to those of EX. LA-EX release from microspheres was fairly well-sustained compared to that of EX microspheres. Additionally, LA-EX-loaded microspheres were more effective in lowering nonfasting blood glucose concentrations than EX microspheres. These findings suggest that LA-EX have the same efficacy as EX and that encapsulating LA-EX into microspheres can achieve better efficacy for the long-term type 2 diabetes mellitus treatment. Graphical AbstractKeywords
This publication has 17 references indexed in Scilit:
- Bifunctional PEGylated Exenatide-Amylinomimetic Hybrids to Treat Metabolic Disorders: An Example of Long-Acting Dual Hormonal TherapeuticsJournal of Medicinal Chemistry, 2013
- Stability of exenatide in poly(d,l-lactide-co-glycolide) solutions: A simplified investigation on the peptide degradation by the polymerEuropean Journal of Pharmaceutical Sciences, 2013
- An Evidence-Based and Practical Approach to Using Bydureon in Patients With Type 2 DiabetesThe Journal of the American Board of Family Medicine, 2013
- Minimizing acylation of peptides in PLGA microspheresJournal of Controlled Release, 2012
- Encapsulation of Exenatide in Poly-( d,l -Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 DiabetesDiabetes Technology & Therapeutics, 2011
- Reversible Blocking of Amino Groups of Octreotide for the Inhibition of Formation of Acylated Peptide Impurities in Poly(Lactide-co-Glycolide) Delivery SystemsAAPS PharmSciTech, 2011
- The Current Status of Exenatide Once WeeklyClinical Medicine Insights: Therapeutics, 2011
- The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeuticsJournal of Controlled Release, 2010
- Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogsJournal of Controlled Release, 2010
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006